These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 16006570)

  • 1. Metabolism and disposition of imatinib mesylate in healthy volunteers.
    Gschwind HP; Pfaar U; Waldmeier F; Zollinger M; Sayer C; Zbinden P; Hayes M; Pokorny R; Seiberling M; Ben-Am M; Peng B; Gross G
    Drug Metab Dispos; 2005 Oct; 33(10):1503-12. PubMed ID: 16006570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects.
    Bolton AE; Peng B; Hubert M; Krebs-Brown A; Capdeville R; Keller U; Seiberling M
    Cancer Chemother Pharmacol; 2004 Feb; 53(2):102-6. PubMed ID: 14605865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disposition of imatinib and its metabolite CGP74588 in a patient with chronic myelogenous leukemia and short-bowel syndrome.
    Beumer JH; Natale JJ; Lagattuta TF; Raptis A; Egorin MJ
    Pharmacotherapy; 2006 Jul; 26(7):903-7. PubMed ID: 16803422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of imatinib mesylate in end stage renal disease. A case study.
    Pappas P; Karavasilis V; Briasoulis E; Pavlidis N; Marselos M
    Cancer Chemother Pharmacol; 2005 Oct; 56(4):358-60. PubMed ID: 15883819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults.
    Menon-Andersen D; Mondick JT; Jayaraman B; Thompson PA; Blaney SM; Bernstein M; Bond M; Champagne M; Fossler MJ; Barrett JS
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):229-38. PubMed ID: 18398615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects.
    Dutreix C; Peng B; Mehring G; Hayes M; Capdeville R; Pokorny R; Seiberling M
    Cancer Chemother Pharmacol; 2004 Oct; 54(4):290-4. PubMed ID: 15138710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of St John's wort on imatinib mesylate pharmacokinetics.
    Frye RF; Fitzgerald SM; Lagattuta TF; Hruska MW; Egorin MJ
    Clin Pharmacol Ther; 2004 Oct; 76(4):323-9. PubMed ID: 15470331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolism and disposition of vatalanib (PTK787/ZK-222584) in cancer patients.
    Jost LM; Gschwind HP; Jalava T; Wang Y; Guenther C; Souppart C; Rottmann A; Denner K; Waldmeier F; Gross G; Masson E; Laurent D
    Drug Metab Dispos; 2006 Nov; 34(11):1817-28. PubMed ID: 16882767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolism and disposition of dasatinib after oral administration to humans.
    Christopher LJ; Cui D; Wu C; Luo R; Manning JA; Bonacorsi SJ; Lago M; Allentoff A; Lee FY; McCann B; Galbraith S; Reitberg DP; He K; Barros A; Blackwood-Chirchir A; Humphreys WG; Iyer RA
    Drug Metab Dispos; 2008 Jul; 36(7):1357-64. PubMed ID: 18420784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588.
    le Coutre P; Kreuzer KA; Pursche S; Bonin Mv; Leopold T; Baskaynak G; Dörken B; Ehninger G; Ottmann O; Jenke A; Bornhäuser M; Schleyer E
    Cancer Chemother Pharmacol; 2004 Apr; 53(4):313-23. PubMed ID: 14658008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disposition and metabolism of radiolabeled casopitant in humans.
    Pellegatti M; Bordini E; Fizzotti P; Roberts A; Johnson BM
    Drug Metab Dispos; 2009 Aug; 37(8):1635-45. PubMed ID: 19420128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors.
    Delbaldo C; Chatelut E; Ré M; Deroussent A; Séronie-Vivien S; Jambu A; Berthaud P; Le Cesne A; Blay JY; Vassal G
    Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6073-8. PubMed ID: 17062683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imatinib mesylate and metabolite concentrations in maternal blood, umbilical cord blood, placenta and breast milk.
    Russell MA; Carpenter MW; Akhtar MS; Lagattuta TF; Egorin MJ
    J Perinatol; 2007 Apr; 27(4):241-3. PubMed ID: 17377606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [(14)C]linezolid to healthy human subjects.
    Slatter JG; Stalker DJ; Feenstra KL; Welshman IR; Bruss JB; Sams JP; Johnson MG; Sanders PE; Hauer MJ; Fagerness PE; Stryd RP; Peng GW; Shobe EM
    Drug Metab Dispos; 2001 Aug; 29(8):1136-45. PubMed ID: 11454733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans.
    Prakash C; Kamel A; Gummerus J; Wilner K
    Drug Metab Dispos; 1997 Jul; 25(7):863-72. PubMed ID: 9224781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metronidazole leads to enhanced uptake of imatinib in brain, liver and kidney without affecting its plasma pharmacokinetics in mice.
    Tan SY; Kan E; Lim WY; Chay G; Law JH; Soo GW; Bukhari NI; Segarra I
    J Pharm Pharmacol; 2011 Jul; 63(7):918-25. PubMed ID: 21635257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The kinetic deuterium isotope effect as applied to metabolic deactivation of imatinib to the des-methyl metabolite, CGP74588.
    Manley PW; Blasco F; Mestan J; Aichholz R
    Bioorg Med Chem; 2013 Jun; 21(11):3231-9. PubMed ID: 23611771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I, open-label, mass balance study of [(14)C] dacomitinib (PF-00299804) in healthy male volunteers.
    Bello CL; Smith E; Ruiz-Garcia A; Ni G; Alvey C; Loi CM
    Cancer Chemother Pharmacol; 2013 Aug; 72(2):379-85. PubMed ID: 23760812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteers.
    Waldmeier F; Glaenzel U; Wirz B; Oberer L; Schmid D; Seiberling M; Valencia J; Riviere GJ; End P; Vaidyanathan S
    Drug Metab Dispos; 2007 Aug; 35(8):1418-28. PubMed ID: 17510248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioequivalence, safety, and tolerability of imatinib tablets compared with capsules.
    Nikolova Z; Peng B; Hubert M; Sieberling M; Keller U; Ho YY; Schran H; Capdeville R
    Cancer Chemother Pharmacol; 2004 May; 53(5):433-8. PubMed ID: 15132131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.